Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers Get access Arrow Jul 10, 2025 | Lymphopenia
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation Feb 29, 2024 | Uncategorized
Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting Jul 19, 2023 | Uncategorized
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition Jul 10, 2023 | Uncategorized
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy Jul 10, 2023 | Uncategorized
